ACH 126443; Beta-L-Fd4C

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 核苷和核苷酸类似物
• 英文名称: ACH 126443; Beta-L-Fd4C
• 英文别名: 4-amino-5-fluoro-1-[5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2-one
• 化学式: C₉H₁₀FN₃O₃
• 分子量: 227.19
• InChiKey: HSBKFSPNDWWPSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  88.2
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Low dose therapy for treating viral infections
  申请人：Pottage John

  公开号：US20070208047A1

  公开（公告）日：2007-09-06

  A method of treating viral infections, particularly Hepatitis B (HBV) and Human Immunodeficiency Virus (HIV), by administering a low dose of Elvucitabine to a patient suffering viral infection is provided herein. The Elvucitabine dosages provided herein for effective anti-viral therapy are approximately 10-fold less than the effective dosages of currently marketed reverse transcriptase inhibitors. The Elvucitabine dosage may be given BID, daily, once every 48 hours, or once weekly. Also provided herein are packaged pharmaceutical formulations comprising Elvucitabine and instructions for treating a viral infection by administering a low BID, daily, once/48 hour, or weekly dosage of Elvucitabine. The low dose Elvucitabine formulations provided herein have the additional benefit of improving patient compliance with anti-viral therapy.
• US7741334B2
  申请人：——

  公开号：US7741334B2

  公开（公告）日：2010-06-22
• [EN] LINE-1 INHIBITORS AS COGNITIVE ENHANCERS<br/>[FR] INHIBITEURS DE LINE-1 UTILISÉS EN TANT QU'ACTIVATEURS COGNITIFS
  申请人：[en]TRANSPOSON THERAPEUTICS, INC.

  公开号：WO2022256625A1

  公开（公告）日：2022-12-08

  The present disclosure provides methods of enhancing cognition, inhibiting cognitive decline, treating or preventing a cognitive deficit disorder, or treating or preventing Creutzfeldt-Jakob disease (CJD) in a subject in need thereof comprising administering a LINE-1 inhibitor, or a pharmaceutical composition thereof, to the subject.